Sunshine Biopharma Inc. has entered an agreement with Lonza for the manufacture of its anti-cancer drug, Adva-27a. Lonza will begin manufacturing at its Nansha, China facility with the remaining key steps to be carried out at its high containment cytotoxic facility in Visp, Switzerland. 
 
“We are delighted to have a global leader like Lonza as our manufacturing partner,” said Dr. Steve N. Slilaty, president and chief executive officer of Sunshine Biopharma. “We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts.”
 
“We are very excited to be working with Sunshine Biopharma on the development of their promising anti-cancer compound,” said James Leresche, Ph.D., head of Lonza’s Chemical Development Services. “This development project is an example of Lonza’s support and commitment to emerging companies with innovative and potentially life-saving treatments like Adva-27a.”